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Abstract
Esophageal cancer is one of the most unknown and 
deadliest cancers worldwide, mainly because of its 
extremely aggressive nature and poor survival rate. 
Esophageal cancer is the 6th leading cause of death 
from cancer and the 8th most common cancer in 
the world. The 5-year survival is around 15%-25%. 
There are clear differences between the risk factors of 
both histological types that affect their incidence and 
distribution worldwide. There are areas of high incidence 
of squamous cell carcinoma (some areas in China) 
that meet the requirements for cost-effectiveness of 
endoscopy for early diagnosis in the general population 
of those areas. In Europe and United States the 
predominant histologic subtype is adenocarcinoma. The 
role of early diagnosis of adenocarcinoma in Barrett’s 
esophagus remains controversial. The differences in the 
therapeutic management of early esophageal carcinoma 
(high-grade dysplasia, T1a, T1b, N0) between different 
parts of the world may be explained by the number of 
cancers diagnosed at an early stage. In areas where 
the incidence is high (China and Japan among others) 
early diagnoses is more frequent and has led to the 
development of endoscopic techniques for definitive 
treatment that achieve very effective results with a 
minimum number of complications and preserving the 
functionality of the esophagus.
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Core tip: Esophageal cancer is a disease with a non-
negligible impact, being the 6th leading cause of death 
from cancer, and with a very high morbidity and 
mortality due to diagnosed in advanced stages. A better 
understanding of the epidemiology, the natural history, 
and the risk factors could lead to an earlier diagnosis 
and treatment by endoscopic methods or by other less 
aggressive techniques. As a result, we could improve 
treatment outcomes, even though less aggressive 
modalities. This article provides a global perspective by 
comparing the management of esophageal cancer in 
Western and Eastern countries with particular emphasis 
on current prevention strategies. 
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EPIDEMIOLOGY OF ESOPHAGEAL 
CANCER
Esophageal cancer is the 6th leading cause of death 
from cancer and the 8th most common cancer in the 
world. The 5-year survival is around 15%-25% and 
the best results are related to early diagnosis, which is 
commonly known as "early stages"[1]. 
Esophageal squamous cell carcinoma is the 
predominant histological type worldwide. However, 
at present, in countries like United States, Australia, 
United Kingdom and Western Europe (Finland, France, 
Norway), there is a preponderance of adenocarcinoma 
subtype, having squamous carcinoma moved to 
second place[1]. The so-called “Asian Esophageal 
Cancer Belt” encompasses areas such as Turkey, Iran, 
Kazakhstan and northern and central China, with 
an estimated esophageal squamous carcinoma of 
more than 100 cases/100000 person-years. Another 
area with high incidence of squamous cell carcinoma 
is southeastern Africa, with similar rates to those 
observed in Eastern countries. In the United States, 
from 1975-2004, the age-adjusted incidence in white 
males has increased from 5.76 to 8.34 cases/100000 
person-years at the expense of the adenocarcinoma 
histological subtype. Nevertheless squamous 
carcinoma remains the most common subtype in 
American black males, but still adenocarcinoma, is one 
of the few cancers that contributes to an increased 
mortality from cancer among American men[2]. The 
trend towards dominance of adenocarcinoma subtype 
is not limited only to North America. In European 
countries like the United Kingdom, France or Norway 
the age-adjusted incidence increased by 39.6% for 
men and 37.5% for women in the last five years[1]. 
There is also a significant difference between gender 
distributions; the incidence of this disease is about 
2-4 fold higher among males compared to females[3]. 
The incidence rates of squamous neoplasia in men 
in the territory of “Asian Esophageal Cancer Belt” 
are around 23 cases/100000 person-years and 16 
cases/100000 person-years for females. In South 
Africa similar rates for males have been estimated[4]. 
Mortality rates follow, overall, a major parallelism with 
incidence rates in each country[5] (Figure 1). Regarding 
race, age-adjusted mortality for black individuals have 
a tendency to decrease, but still it is two-fold higher 
compared to Caucasians (7.79 vs 3.96, P < 0.05)[2].
RISK FACTORS
Risk factors of esophageal cancer are slightly different 
between the two major subtypes.
Risk factors for squamous carcinoma
Gender and race: Squamous cell carcinoma is the 
most frequent histological type in black individuals and 
white women, while adenocarcinoma is predominant in 
white men (P < 0.001)[2]. The incidence of esophageal 
squamous cell carcinoma is generally higher in men 
than women in most countries, and black men, 
compared to whites in the United States[4].
Smoking: Smoking is one of the major risk factor 
for developing esophageal squamous carcinoma. 
Smokers have a 5-fold risk of developing this disease 
compared to non-smokers[4]. However, there are parts 
of the world where smoking is not such an important 
risk factor and racial differences could account for 
these geographical differences. In a prospective study 
of risk factors for esophageal cancer in the province 
of Linxia, China, smoking was not an important risk 
factor compared to other parts of the world, while diet-
related factors seem to play a major role in esophageal 
carcinogenesis. A study from Taiwan compared current 
and former smokers to people who never smoked 
and found that the OR was 4.2 and 3.4 respectively 
for smokers and former smokers compared to people 
without this habit[4].
Alcohol: Alcohol is a clear risk factor for squamous 
carcinoma. The relative risk (RR) increases with the 
amount of alcohol ingested varying between 1.8 and 
7.4 depending on the weekly volume[4]. The intake of 
certain types of drink creates worldwide “hot spots” of 
squamous cell carcinoma of the esophagus in areas 
of Northern France consuming Brandie, corn beer 
in Southeast Africa, distilled sugary drinks in Puerto 
Rico, or certain whiskies in Carolina, United States. 
In Northern China, alcohol is not consumed regularly 
and therefore the risk associated with this habit is not 
relevant[4].
Diet and nutrients: Tea, mate and coffee have been 
extensively studied as potential risk factors associated 
with esophageal carcinoma and its geographical 
distribution, particularly in regions of South America. 
There is little evidence for carcinogenicity relationship 
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through its components except for mate, which 
has been linked for both amount consumed and 
temperature[4]. Foods rich in nitrogenous components 
are historically related to the high incidence of 
squamous cell carcinoma in certain regions of China. 
A meta-analysis published in 2003, shows an OR of 2 
for individuals who eat foods rich in such compounds 
compared to those who do not[4].
The “chewers of areca nut” (often mixed with 
tobacco), are common in regions such as Southeast 
Asia and India and have been linked to the develop-
ment of squamous carcinoma. In Taiwan, where the 
tobacco is not included in the chewable mixture, the 
OR for chewers is 2.3[4]. Similarly, people living in 
developing countries that have significant deficits of 
minerals and vitamins, mainly due to low intake of 
foods like fruits and vegetables also have an OR of 2[4].
Genetics: There are conditions with a genetic basis, 
such as Tylosis, an autosomal dominant disease, 
that are clearly related to the development of 
esophageal squamous carcinoma. Familial aggregation 
in population of high incidence of esophageal 
carcinoma, such as northern regions of China has 
also been reported[4]. Four genome-wide association 
studies (GWAS), three of them conducted in Chinese 
population and one in Japanese population have shown 
genetic susceptibility factors in the development of 
squamous carcinoma, especially in heavy alcohol and 
tobacco users. Two nucleotide polymorphisms (SNPs, 
single nucleotide polymorphisms) deserve special 
attention because encode enzymes metabolizing 
alcohol: alcohol dehydrogenase 1B (rs1229984, OR = 
1.79) and aldehyde dehydrogenase 2 family (rs671, 
OR = 1.67). Other GWAS found association at two 
loci, one located in the enzyme phospholipase C and 
another in a particular region of chromosome 20 
(C20orf54)[3]. Regarding association with squamous 
carcinoma a GWAS dataset that included 453852 SNPs 
from 1898 squamous carcinoma patients and 2100 
control subjects of Chinese population was reviewed. 
The authors identified candidate causal SNPs, and 
pathways (ICSNPathway) analysis identified seven 
candidate SNPs, five genes, and seven pathways, 
which together revealed seven hypothetical biological 
mechanisms. The three strongest hypothetical 
biological mechanisms were rs4135113, rs1800450 
and rs3769823[6].
Risk factors for esophageal adenocarcinoma 
Gender and race: The incidence of esophageal 
adenocarcinoma is 8-fold more common in men than 
in women and 5-fold more common in whites than in 
blacks in the United States[4].
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Figure 1  Estimated age-standardized rates per 100000. Year 2012. Modified from IARC, GLOBOCAN[5].
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incidence of GERD, and second a hormonal-dependent 
mechanism mainly mediated by inflammatory markers 
that are secreted by adipocytes[4].
Tobacco, alcohol and nutritional deficit: Alcohol 
is not related to the presence of adenocarcinoma, but 
smoking tobacco is a known risk factor, with an OR of 
2.7 (95%CI: 1.64-4.45) relative to non-smokers[11].
In a Swedish population study, an inverse rela-
tionship was found between intake of total dietary fiber 
and the presence of adenocarcinoma of the gastro-
esophageal junction. Similarly, in a United States case-
control study it was found that a diet rich in vitamins, 
fruits and vegetables protect against the development 
of this disease[4].
Drugs: Observational studies with a large number 
of patients showed that the use of non-steroidal 
anti-inflammatory drugs (NSAIDs), proton pump 
inhibitors (PPIs) and statins in patients with BE, 
reduced the progression to adenocarcinoma[4]. The 
most studied agents have been acid suppressants. 
A systematic review with meta-analysis of studies 
evaluating the association between PPIs and histamine 
receptor antagonists (H2RAs) and risk of esophageal 
adenocarcinoma or high-grade dysplasia (HGD) 
in patients with BE has been recently published. 
The authors identified seven observational studies 
(2813 patients with BE, 317 cases of esophageal 
adenocarcinoma or HGD, 84.4% PPI users). On meta-
analysis, PPI use was associated with a 71% reduction 
in risk of esophageal adenocarcinoma and/or HGD 
in patients with BE (adjusted OR = 0.29; 95%CI: 
0.12-0.79). There was a trend towards a dose-
response relationship with PPI use for > 2-3 years 
protective against esophageal adenocarcinoma or HGD 
[three studies; PPI use > 2-3 years vs < 2-3 years: OR 
= 0.45, (95%CI: 0.19-1.06) vs OR= 1.09 (95%CI: 
0.47-2.56)]. Considerable heterogeneity was observed. 
Two studies reported the association between H2RA 
use and risk of esophageal adenocarcinoma and/or 
HGD (1352 patients with BE, 156 cases of esophageal 
adenocarcinoma, 25.4% on H2RAs), and both studies 
did not show a significant effect[12]. The largest study 
was published short after and challenged these results. 
In such nationwide case-control study carried out 
in Denmark, no cancer-protective effects from PPI’s 
were seen. In fact, among 9883 patients with a new 
diagnosis of BE the authors identified 140 cases with 
incident esophageal adenocarcinomas and/or high-
grade dysplasia, with a median follow-up time of 10.2 
years. The relative risk of esophageal adenocarcinoma 
or high-grade dysplasia was 2.2 (95%CI: 0.7-6.7) and 
3.4 (95%CI: 1.1-10.5) in long-term low- and high-
adherence PPI users respectively. Such results could 
partly be due to confounding by indication or a true 
negative effect from PPIs. Based on these results and 
until the results from future studies can elucidate what 
Gastroesophageal reflux disease and Barrett’s 
esophagus: The prevalence of gastroesophageal 
reflux disease (GERD) in the Western population is 
about 10%-20%, and about 30 to 60 million people in 
the United States. This entity is capable of producing 
esophageal adenocarcinoma directly or, more 
commonly, through an intermediate pre-neoplastic 
lesion, the Barrett's esophagus (BE). The increased 
incidence of BE in the last 30 years, is correlated with 
an increased incidence of adenocarcinoma in the 
same period. Barrett’s esophagus is a pre-malignant 
lesion that develops in 6%-14% of patients with 
GERD and of which, around 0.5%-1% will develop 
adenocarcinoma[4]. In a study performed in Spain, 
the incidence of adenocarcinoma during follow-up 
of patients with BE was 0.48% per year (95%CI: 
0.006%-2.62%), for an incidence of 1 per 210 patient-
years[7]. The largest study is a nationwide, population-
based, cohort study conducted in Denmark, involving 
all patients with BE during the period from 1992 
through 2009, using data from the Danish Pathology 
Registry and the Danish Cancer Registry. The study 
included 11028 patients with BE for a median of 5.2 
years. The incidence rate for adenocarcinoma was 1.2 
cases per 1000 person-years (95%CI: 0.9-1.5). As 
compared with the risk in the general population, the 
RR of adenocarcinoma among patients with BE was 
11.3 (95%CI: 8.8-14.4). However, the annual risk 
of esophageal adenocarcinoma was 0.12% (95%CI: 
0.09-0.15). Current surveillance guidelines assume 
a risk for adenocarcinoma of 0.5%-1%, far from the 
results obtained in this study. Detection of low-grade 
dysplasia was associated with an incidence rate for 
adenocarcinoma of 5.1 cases per 1000 person-years 
compared to 1.0 case per 1000 person-years among 
patients without dysplasia. These data question the 
rationale for ongoing surveillance in patients who have 
Barrett’s esophagus without dysplasia[8].
Obesity: Obesity is a major and consistent risk factor 
for the development of esophageal adenocarcinoma. 
It has become a serious public-related disease in 
developed countries. By 2015, an estimated 75% of 
the American people will be overweight (BMI > 25) 
and 41% obese (BMI > 30). The OR of developing 
adenocarcinoma is 1.52 (95%CI: 1.33-1.74, P 
< 0.0001) for those with BMI in the 25-30 rank 
compared with those who have normal-weight. A 
high BMI (> 25) was associated with an increased 
risk of oesophageal adenocarcinoma (males, OR = 
2.2; 95%CI: 1.7-2.7; females, OR = 2.0; 95%CI: 
1.4-2.9)[9]. Higher levels of BMI were associated 
with increased risk of oesophageal adenocarcinoma 
(overweight males, OR = 1.8; 95%CI: 1.5-2.2; obese 
males, OR = 2.4; 95%CI: 1.9-3.2)[10]. Two main 
mechanisms have been proposed for the development 
of esophageal adenocarcinoma in obese patients. First, 
a physical mechanism involving an increase in the 
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the association might be, continuous PPI therapy might 
not be necessary in all patients and could be directed 
at symptom control[13].
Genetic aspects: Very recently, it has been demon-
strated using GWAS, that risk of BE and esophageal 
adenocarcinoma is influenced by many germline 
genetic variants of small effect and that shared 
polygenic effects contribute to the risk of these 
two diseases. In fact, the authors found that the 
genetic correlation between BE and esophageal 
adenocarcinoma was high (rg = 1.0; SE = 0.37) and 
estimated a statistically significant polygenic overlap 
between BE and esophageal adenocarcinoma [one-
sided P = 1 × 10(-6)]. These data strongly suggest 
that shared genes underlie the development of BE and 
esophageal adenocarcinoma[14].
GWAS type studies have also been conducted to 
elucidate susceptibility loci. The first genome-wide 
association study of esophageal adenocarcinoma, 
together with BE has been recently published. The 
most significant results were for cancer and pre-cancer 
combined suggesting that much of the genetic basis for 
esophageal adenocarcinoma lies in the development of 
BE, rather than its to esophageal adenocarcinoma. The 
authors found three novel genome-wide significant loci 
for esophageal adenocarcinoma and BE combined, and 
extended existing findings at the FOXF1 and HLA loci. 
One of the novel regions is chromosome 3p13, near 
FOXP1, a gene encoding a transcription factor, which 
regulates esophageal development. Interestingly, two 
of the other regions (BARX1/9q22.32 and FOXF1/
16q24.1) contain risk associated SNPs which disrupt 
binding of FOXP1. Further dissection of these loci is 
likely to lead to insights into the etiology of this rapidly 
fatal cancer[15] (Table 1).
EARLY DIAGNOSIS AND SCREENING OF 
ESOPHAGEAL CARCINOMA
Esophageal cancer is a health problem worldwide 
with high mortality due to its natural history and the 
common diagnosis in advanced stages. Therefore, its 
detection at an early stage would improve outcomes of 
mortality significantly. Squamous dysplasia is the pre-
cursor lesion of esophageal squamous cell carcinoma; 
Barrett’s esophagus is the pre-neoplastic lesion 
preceding adenocarcinoma[16].
Screening and surveillance of esophageal 
adenocarcinoma
Screening of BE-associated adenocarcinoma by 
endoscopy is a worldwide clinical practice although 
it has not been proven cost-effective. According to 
current guidelines, random endoscopic biopsies should 
be taken in all 4 quadrants and each 2 cm of columnar 
epithelium, and ideally performed with high-resolution 
endoscopes and NBI (narrow banding imaging)[17].
The results of large cohort studies suggest that 
the annual cancer risk for patients with non-dysplastic 
Barrett’s esophagus is low in European populations 
(0.12%-0.40% per year)[8]. Dysplasia within BE lesions 
signals a marked increase in cancer risk: the annual 
risk is approximately 1% for patients with low-grade 
dysplasia and more than 5% for patients with high-
grade dysplasia. However, 80% to 90% of cases of 
esophageal adenocarcinoma are diagnosed in patients 
without known BE. Endoscopic screening results 
in detection of BE in 6% to 12% of patients with 
prolonged GERD symptoms, most frequently white 
men older than 50 years of age[18].
A recent review by Spechler and Souza suggests 
that people with chronic GERD symptoms and at least 
1 risk factor for esophageal carcinoma are suitable for 
active endoscopic screening for Barrett’s esophagus 
and early adenocarcinoma with adequate surveillance 
depending on the lesion found on the index endoscopy 
and pathology (Figure 2). The main caveat of such 
strategy is that the target population focuses on 
GERD patients although around 40% of esophageal 
adenocarcinomas have no prior history of GERD[19].
In 2006, a systematic review, expert workshop 
and economic modelling was performed focused 
on Surveillance of BE. Such study identified 3 cost-
utility analyses of surveillance of BE that used Markov 
modeling and confined their analysis to 50- or 55-year-
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Table 1  Risk factors for squamous cell carcinoma and adenocarcinoma of the esophagus
Risk factor Squamous cell carcinoma Adenocarcinoma
Geography Southeastern Africa, Asia, Iran, South America Western Europe, North America (United States), Australia
Race Black > White White > Black
Gender Male > Female Male > Female
Alcohol ++++ -
Tobacco ++++ ++
Obesity - +++
GERD - ++++
Diet: Low fruits and vegetables ++ +
Socioeconomic conditions ++ -
Genetic aspects ++ +
GERD: Gastroesophageal reflux disease; +: Associated risk; -: No risk associated. Modified from[4].
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old white men with GERD symptoms. In one study, 
the authors concluded that the only cost-effective 
strategy was once in a lifetime screening of 50-year-
old white men with GERD, followed by surveillance 
of those with dysplasia only. In the other 2 studies 
(performed by the same group) surveillance of BE 
every 5 years compared with no surveillance was cost-
effective; however the model was very sensitive to the 
incidence of adenocarcinoma and quality of life (utility 
value) in the post-esophagectomy state. Moreover, 
the incremental cost-effectiveness ratio for 5-yearly 
surveillance was no longer within the range usually 
considered cost-effective[20].
These models are American, so there are almost 
certainly differences in practice from Europe and 
possible underlying differences in the epidemiology 
and natural history of the disease. In European public 
services there is a major difficulty in knowing what 
proportion of patients with GERD have an endoscopy 
and at what stage of the disease, whereas in the 
United States, those who present to health services 
are more likely to be investigated at an earlier stage. 
The costs of the procedures involved are also likely to 
be very different.
They key of surveillance may underlie on what 
patients may benefit from it. Is dysplasia a good 
marker? Should genetic markers be used? A recent 
cost-utility analysis from Australia compared (1) No 
surveillance; (2) 2-yearly endoscopic surveillance 
of patients with non-dysplastic BE and 6-monthly 
surveillance of patients with low-grade dysplasia; and 
(3) a hypothetical strategy of biomarker-modified 
surveillance. In a total of 2040 patient-years of follow-
up and by using best available estimates of the 
malignant potential of BE, endoscopic surveillance of 
patients with non-dysplastic BE is unlikely to be cost-
effective for the majority of patients and depends 
heavily on progression rates between dysplasia 
grades. However, strategies that modify surveillance 
according to cancer risk might be cost-effective, if 
high-risk individuals can be identified and prioritized 
for surveillance[21]. However, unless newly emerging 
technologies improve the quality-adjusted survival 
benefit conferred by endoscopic surveillance, current 
strategies are unlikely to be cost-effective in Europe. 
Obsolete assumptions and incomplete analyses reduce 
the quality of published evaluations. For these reasons 
new evaluations are required that encompass the 
growing evidence base for new technologies, such as 
new endoscopic therapies for high-grade dysplasia and 
intramucosal cancer[22].
Another fact that should be added in the evaluation 
is that, despite the absence of direct evidence from 
randomized trials, most but not all observational studies 
have shown that patients in whom adenocarcinoma 
is detected during endoscopic surveillance for BE are 
more likely to have early-stage cancer, receive curative 
therapy, and survive longer than symptomatic patients 
in whom adenocarcinoma is detected during the clinical 
workout[18].
Squamous cell carcinoma: Need or not a screening 
program?
Esophageal squamous cell carcinoma is the predominant 
histologic subtype in Asia and the incidence and 
mortality are higher in China than in Japan. In Japan, 
the incidence of this disease is declining from the late 
90 s to the present. By contrast, in China, esophageal 
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Chronic GERD symptoms and ≥ 1 risk 
factor (1) for esophageal adenocarcinoma
Consider screening endoscopy for Barrett’s esophagus
No Barrett’s esophagus; No further screening Barrett’s esophagus
No dysplasia Suspected low-grade dysplasia Suspected high grade dysplasia or 
intramucosal carcinoma
Have diagnosis confirmed by expert pathologist
Every 3-5 yr endoscopy Every 6-12 mo endoscopy or endoscopy 
eradication therapy
Endoscopic eradication 
therapy
Figure 2  Algorithm for the screening surveillance, and management of Barrett’s esophagus. Risk factors for esophageal adenocarcinoma: age > ó = 50 years, 
male sex, white race, hiatal hernia, elevated body-mass index, intra-abdominal body-fat distribution, or tobacco use. Modified from reference[19].
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cancer is the 4th most frequently diagnosed cancer and 
the 4th leading cause of death from cancer. Incidence 
rates are higher in rural areas of China compared to 
urban areas, especially in regions such as Henan, Hebei, 
Linxia and Shanxi[23]. As mentioned before, squamous 
dysplasia is a precursor lesion of squamous carcinoma. 
It is hardly detectable in asymptomatic individuals and 
there is no standardized screening program to detect 
this condition[23].
In Japan there are controversies about whether 
dysplasia should be actively detected by gastro-
enterologists. There are no reliable data on the actual 
prevalence of dysplasia in Japanese asymptomatic 
patients, but a recent study of 1345 asymptomatic 
individuals, who underwent endoscopy during a health 
check, found a prevalence of dysplasia of 3% in this 
population. There are no prospective studies and the 
relationship between dysplasia and squamous carcinoma 
development in this population is still unknown[23].
In China, endoscopic screening in high-risk areas 
(defined as an incidence higher than 30 cases per 
100000 inhabitants per year) has been shown to 
detect precursor lesions in asymptomatic patients 
with dysplasia, with high rates of what is known as 
“esophageal early cancer”. The main dysplastic lesion 
associated with esophageal squamous cell carcinoma 
in prospective population studies in the Chinese 
region of Linxia is the high-grade dysplasia, which is 
associated with an RR of 28.3 (95%CI: 15.3-52.3) for 
developing the disease compared to patients who have 
a normal esophageal mucosa[23,24].
Endoscopy: Endoscopy is the gold standard for 
the diagnosis of pre-cancerous squamous lesions. 
Squamous dysplasia may go undetected when using 
standard endoscopy and therefore chromoendoscopy 
techniques have been suggested to improve the 
performance of the test. The most simple and effective 
for the detection of squamous dysplasia is Lugol 
staining. The sensitivity and specificity of white-light 
endoscopy for the detection of high-grade dysplasia 
and cancer is 62% and 79% respectively, compared 
with a much higher sensitivity of 96%, at the expense 
of a slight loss of specificity of 63%, when using Lugol 
chromoendoscopy[16].
Most of the studies, if not all, have been performed 
in Asia where the incidence of squamous carcinoma is 
high. The prevalence of low, medium, high grade and 
invasive carcinoma, using Lugol chromoendoscopy, 
are 28%, 21.9%, 6.3% and 0% to 9.5% respectively 
in expert hands, and many of these lesions can be 
treated with endoscopic resection[16]. In this regard, a 
prospective population study was conducted in 2014 
in Henan, one of the areas of Northern China with high 
incidence of esophageal carcinoma, in the context of a 
screening program with biopsies taken and guided by 
chromoendoscopy. A total of 36154 people between 
40 and 69 years were examined. The study detected 
7.1% of people with low-grade dysplasia, 2.3% with 
intermediate grade dysplasia and 1.6% with cancerous 
lesions, being 87.32% of them early carcinomas (high-
grade dysplasia, carcinoma mucosa-submucosa) 
cases[25].
The results of several cost-benefit studies about 
endoscopic screening of esophageal squamous 
carcinoma have shown that such strategy is only cost-
effective in areas of high incidence of squamous cell 
carcinoma, such as in Northern and rural areas of 
China. However, some variations may occur even in 
high-risk areas. The geographical and the economic 
status of the region have a great impact in the onset 
of esophageal carcinoma regarding the age of onset, 
the number needed to screen, the precursor lesions 
that have to be identified and the intervals for a proper 
surveillance in people with such lesions[26,27].
A recent study, based on economic parameters 
and management, made a comparison between 12 
different existing screening methods in high-risk/high 
incidence of squamous cell carcinoma in China. The 
two key strategies to be followed to ensure cost-
effective programs taking into account the acceptance 
of the population and the distribution of wealth in 
different regions were: (1) screening once throughout 
life and starting at the age of 50, following up after 
5 years of detecting low-grade dysplasia and 3 years 
after intermediate-grade dysplasia, for areas with 
limited access to healthcare, impoverished and with a 
difficult track the target population economy[26]; and 
(2) screening three times over life, starting at the 
age of 40, and monitoring low-grade dysplasia and 
intermediate-grade dysplasia as above, for areas with 
appropriate access to health care, and economies that 
are more advanced and good monitoring program by 
the target population[26].
One of the questions is whether these results 
can be applied to Western countries. There are 
no European studies suggesting that endoscopic 
screening for squamous esophageal carcinoma is 
either necessary or cost-effective. The low incidence 
of squamous esophageal carcinoma in the European 
population and the predominance of public health 
systems might be some of the main reasons why 
screening of this condition is not an option even in 
individuals with risk factors.
Other screening techniques: There are areas in 
the world with high incidence of squamous carcinoma, 
beyond those already mentioned, where screening 
program using the gold standard technique with 
Lugol chromoendoscopy have not been shown to 
be cost-effective. An Iranian review published in 
2013 suggested that new screening strategies, 
cheaper and more effective, should be tracked. They 
propose combining the individual risk factors of 
patients with cytology techniques without endoscopy 
and/or tissue or serum markers of risk detected 
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enzimoimmunoassay techniques or micro-RNA[28].
There is a relatively large number of extraction 
techniques without endoscopic for esophageal cytology 
which include inflatable balls and sponges, recently 
developed, but these techniques have a sensitivity of 
only 24%-47% for dysplasia-cancer and 18%-44% for 
cancer, despite having good specificity of 81%-92% 
and 99%-100% for dysplasia-cancer and cancer 
respectively. The low number of suitable samples and 
low sensitivity makes them unsuitable for effective 
screening[16].
Very few studies looking at blood biomarkers on 
people of countries with high incidence of squamous 
carcinoma have been performed, but most suggest that 
these should be used in the future in combination with 
other screening techniques to optimize the results[16].
TREATMENT OF EARLY ESOPHAGEAL 
CARCINOMA
Early esophageal carcinoma (EEC) is defined as those 
early stages in which the neoplastic involvement does 
not exceed the submucosa, and there are no nodes 
involved (DAG, T1a, T1b, N0)[29,30] (Table 2, Figure 3).
There are big differences among treatment for 
early esophageal cancer between Western and Asian 
countries. In fact, the Asian attitude is more aggressive 
in managing these patients.
Management of ECC in Western countries
Most Western studies convey the idea that the rate of 
lymph node metastasis in T1b tumors is too high to be 
considered a safe endoscopic therapy as a definitive 
treatment for this neoplastic disease. It is estimated 
that the risk of nodal metastases in tumors confined to 
the mucosa (T1a), mainly adenocarcinomas in clinical 
practice, is 1%-2%, therefore, an endoscopic local 
treatment may be considered sufficient as definitive 
treatment. In tumors invading the submucosa (T1b), 
the risk of nodal metastases exceeds 10%, therefore 
a definitive endoscopic treatment is not feasible 
in principle[31]. In this type of tumor stages (high-
grade dysplasia, T1a) the most common therapeutic 
approach is the combination of endoscopic resection 
techniques by means of mucosal resection (EMR) to 
remove the neoplastic tissue associated with ablative 
techniques such as radiofrequency to remove the 
remaining metaplastic/dysplastic residual tissue. Its 
therapeutic efficacy is up to 98%, and its potential 
complications include bleeding, perforation and 
residual stenosis[31,32].
For stage T1a, esophagectomy is seen today as a 
second treatment option, with a success rate similar to 
endoscopic cancer but with a much larger treatment 
morbidity. However, esophagectomy should be 
considered in patients in whom the risk of recurrence is 
considered high (7%-30%), such as multifocal lesions 
and long BE segments associated with neoplasia where 
it is not possible to associate ablative techniques[33].
A review of 46 studies involving 7645 patients with 
esophageal cancer T1N0 concluded that in T1b sm1 
adenocarcinomas, well or moderately differentiated 
without lymphovascular invasion or lymph node 
metastasis, endoscopic treatment is the preferred 
option because the rate of lymph node involvement is 
lower than suspected (6% in sm1). However, in m3 
T1a squamous carcinomas, lymph node involvement is 
higher than previously presumed and esophagectomy 
with lymphadenectomy should be considered[31,32].
Management of EEC in oriental countries
A number of articles from Asia, mainly Japan and 
China, have a more aggressive approach from the 
point of view of endoscopic management of early 
esophageal cancer. T1a and T1b lesions, regardless 
of histological type, with confirmed no lymph node 
metastases, are managed by endoscopy resection, 
since it is considered that this technique has the same 
efficacy as esophagectomy. A recently published 
population-based study comparing the survival of 
both techniques for T0/T1 stages, with a total of 430 
patients who received endoscopic treatment over 1586 
patients who received surgical treatment showed no 
differences in mortality after 2 (endoscopy: 10.5% 
vs 12.7% surgery, P = 0.27) or 5 years (endoscopy: 
36.7% vs 42.8% surgery, P = 0.16) of follow-up[34]. 
The fundamental treatment of neoplasia at this stage 
is suggested to be the combination of definitive 
endoscopic treatments such as EMR or ESD (endoscopic 
submucosal dissection) with ablative treatments to 
eradicate the rest of metaplastic/dysplastic tissue if 
necessary[35].
The main objective of this approach is to preserve 
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Table 2  TNM esophageal cancer
T: Primary tumor:
   Tx: It can not be evaluated
   T0: No evidence of primary tumor
   Tis: High-grade dysplasia (intra-epithelial neoplasia noninvasive)
   T1: Tumor invades own lamina, muscularis mucosae and submucosa:
      T1a: Tumor invades own lamina or muscularis mucosae
      T1b: Tumor invades the submucosa
   T2: Tumor invades the muscularis
   T3: Tumor invades the adventitia
   T4: Tumor invades adjacent structures:
      T4a: Tumor invades resectable pleura, pericardium, or diaphragm
      T4b: Unresectable tumor that invades other adjacent structures: 
aorta, vertebral body, trachea, etc.
N: Regional lymph nodes:
   Nx: They can not be evaluated
   N1: Metastasis in 1-2 regional lymph nodes
   N2: Metastasis in 3-6 regional lymph nodes
   N3: Metastasis in 7 or more regional lymph nodes
M: Distant metastasis:
   M0: None
   M1: There are distant metastases
Modified from AJCC 2010[29].
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the esophagus as a functional organ and avoid the 
morbidity of surgery at that level. The EMR was the 
first endoscopic technique developed. However, it has 
its limitations. In a meta-analysis of five case-control 
studies that included 319 lesions treated with ESD and 
476 lesions treated with EMR it was observed that ESD 
shower better “en bloc” and histologically resection 
rates, and lower recurrence, without increasing the 
incidence of procedure-related complications but at 
the cost of a longer process and higher costs[36]. In 
fact, in a similar meta-analysis of 21 studies, 1152 
patients and 1240 lesions treated with ESD, with an 
average follow-up period between 12 and 53 mo, it 
was observed that the rates of resection as a whole 
were 99% (95%CI: 99%-100%), and R0 resection 
rate of 90%. In lesions less than 25 mm higher a 
percentage of R0 resections (92% vs 85%, P < 0.001) 
was achieved. The complication rate was very low, the 
most significant being stenosis, with an incidence of 5% 
(95%CI: 3%-8%). The authors conclude that it is a 
safe and effective technique[37].
SUMMARY AND CONCLUSIONS
Squamous cell carcinoma is still the most common 
histologic type in the world. The areas with the highest 
incidence are found in Africa and the Middle East. 
The risk factors most frequently involved, are the 
abuse of tobacco and alcohol, as well as mutations 
in metabolizing pathways of these substances, and 
nutritional deficits. In areas of high incidence, defined 
as 30 or more cases per 100000 person-years, 
justified the mass screening of squamous carcinoma, 
a fact that improves detection rates of early squamous 
cell carcinoma and its management without surgery, 
with a high proportion of patients treated with endo-
scopic resection strategy.
There has been a shift from squamous carcinoma 
to adenocarcinoma as the most frequent histological 
type of esophageal carcinoma in fundamental areas of 
Europe such as Norway, United Kingdom, in the United 
States and in Australia. Differentiating risk factors are 
fundamentally obesity, GERD and BE as well as the 
influence of toxics such as tobacco. BE is a precursor of 
adenocarcinoma, but the rate of cancer transformation 
in European and United States populations is low, 
which questions surveillance programs and the search 
for an early diagnosis of adenocarcinoma in BE, which 
is common clinical practice today. In any case, the rate 
of detection of early stage adenocarcinoma is lower 
in Western countries and treatment, therefore, is less 
conservative, with high proportion of patients treated 
with surgical techniques to achieve eradication of the 
disease.
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